- Home
- SGMO vs GNFT Comparison
SGMO vs GNFT Comparison
Compare SGMO & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- GNFT
- Stock Information
- Founded
- SGMO 1995
- GNFT 1999
- Country
- SGMO United States
- GNFT France
- Employees
- SGMO N/A
- GNFT N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMO Health Care
- GNFT Health Care
- Exchange
- SGMO Nasdaq
- GNFT Nasdaq
- Market Cap
- SGMO 122.8M
- GNFT 214.5M
- IPO Year
- SGMO 2000
- GNFT 2019
- Fundamental
- Price
- SGMO $0.53
- GNFT N/A
- Analyst Decision
- SGMO Buy
- GNFT Strong Buy
- Analyst Count
- SGMO 6
- GNFT 1
- Target Price
- SGMO $4.50
- GNFT $13.00
- AVG Volume (30 Days)
- SGMO 5.9M
- GNFT 4.2K
- Earning Date
- SGMO 08-05-2025
- GNFT 04-24-2025
- Dividend Yield
- SGMO N/A
- GNFT N/A
- EPS Growth
- SGMO N/A
- GNFT N/A
- EPS
- SGMO N/A
- GNFT 0.03
- Revenue
- SGMO $63,756,000.00
- GNFT $73,187,701.00
- Revenue This Year
- SGMO N/A
- GNFT $15.98
- Revenue Next Year
- SGMO N/A
- GNFT N/A
- P/E Ratio
- SGMO N/A
- GNFT $123.88
- Revenue Growth
- SGMO 239.92
- GNFT 105.01
- 52 Week Low
- SGMO $0.30
- GNFT $2.55
- 52 Week High
- SGMO $3.18
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SGMO 49.93
- GNFT 46.56
- Support Level
- SGMO $0.50
- GNFT $3.61
- Resistance Level
- SGMO $0.61
- GNFT $3.95
- Average True Range (ATR)
- SGMO 0.05
- GNFT 0.14
- MACD
- SGMO 0.01
- GNFT -0.01
- Stochastic Oscillator
- SGMO 58.45
- GNFT 50.64
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.